CEL-SCI Corporation news

   Watch this stock
Showing stories 11 - 20 of about 87   

Articles published

CVM 1.87 +0.08 (4.47%)
price chart
CEL-SCI Corp (CVM) Responds to FDA for Phase 3 Head and Neck Cancer Trial
CEL-SCI Corporation (NYSE: CVM) today announced that it has responded to the U.S. Food and Drug Administration's (FDA) most recent communication from May 2017 about the clinical hold imposed on the Company's Phase 3 head and neck cancer study ...
CEL-SCI submits FDA response for its Phase 3 head and neck cancer trial  Seeking Alpha
CEL-SCI Corporation (CVM): Analyzing CEO Compensation
Geert Kersten took the reins as CEL-SCI Corporation's (AMEX:CVM) CEO and earned a total compensation of $629,313 over the past year.
This Weeks Target Prices For Cel-Sci Corporation (CVM)  NewsDen
Tag: CEL-SCI Corporation
The European patent office has confirmed it will award CEL-SCI Corporation (NYSEMKT:CVM) a patent for its investigational cancer immunotherapy, Multikine.
Price Target Estimates for CEL-SCI Corporation (CVM)  TRA
Price Target Analysis CEL-SCI Corporation (CVM)  News Oracle
US FDA Removes Clinical Hold on CEL-SCI's Phase 3 Head & Neck Cancer Trial
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced it has received a letter from the U.S.
CEL-SCI Corporation (CVM) Stock: Gaining Big On FDA News  CNA Finance (press release)
Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward  TheStreet.com
CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that it has been awarded a new Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Arthritis and Musculoskeletal and Skin ...
Kura Oncology, Inc. (KURA) has a value of $12.50 per share While CEL-SCI ...  Stocks Gallery
Brokers Issue New Targets On Cel-Sci Corporation (CVM)  Fiscal Standard
CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announces the publication of data from rheumatoid arthritis (RA) studies in Vaccine, a leading peer-reviewed journal for researchers interested in vaccines and vaccination.
DURECT Corporation (DRRX) is at $1.97 per share and CEL-SCI Corporation (CVM ...
In latest trading activity; DURECT Corporation (DRRX) snatched the consideration from Investors, when its current beneficial picture was seen that is promoting good health.
CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announces that it has received the official minutes from its February 8, 2017 meeting with the U.S.
CEL-SCI Corporation (NYSEMKT:CVM) Addresses FDA Partial Clinical Hold  Small Cap Exclusive (press release)
CEL-SCI Corporation (CVM): A Detailed Look at its Institutional Ownership
CEL-SCI Corporation (NYSE:CVM) produced a 16.44% rally since recording the worst price of $1.46. Thanks to the latest -3.95% decrease, it now trades at $1.7.
Significant Movements: CEL-SCI Corporation (CVM), PEDEVCO Corp. (PED)  Click Daily Finance
Cel-Sci Corporation (CVM) Valuation According To Analysts  UK Market News
Eye-Catching Hot Stocks: CEL-SCI Corporation (NYSE: CVM)
On Monday, Shares of CEL-SCI Corporation (NYSE: CVM) expressed a change of -0.55% and is currently trading at $1.82. The stock exchanged hands with 42,373 numbers of shares compared to its average daily volume of 216.15K shares.
Analyst Stock Recommendations For Ternium SA (TX), CEL-SCI Corporation ...  Analyst Journal